Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: A preliminary report

Recent advances have facilitated the use of blood‐derived RNA to conduct genomic analyses of human diseases. This emerging technology represents a rigorous and convenient alternative to traditional tissue biopsy‐derived RNA, as it allows for larger sample sizes, better standardization of technical p...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of medical genetics. Part B, Neuropsychiatric genetics Vol. 133B; no. 1; pp. 1 - 5
Main Authors Tsuang, Ming T., Nossova, Nadine, Yager, Tom, Tsuang, Min-Min, Guo, Shi-Chin, Shyu, Kou Ge, Glatt, Stephen J., Liew, C.C.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 05.02.2005
Subjects
Online AccessGet full text
ISSN1552-4841
1552-485X
DOI10.1002/ajmg.b.30161

Cover

More Information
Summary:Recent advances have facilitated the use of blood‐derived RNA to conduct genomic analyses of human diseases. This emerging technology represents a rigorous and convenient alternative to traditional tissue biopsy‐derived RNA, as it allows for larger sample sizes, better standardization of technical procedures, and the ability to non‐invasively profile human subjects. In the present pilot study, we have collected RNA from blood of patients diagnosed with schizophrenia or bipolar disorder (BPD), as well as normal control subjects. Using microarray analysis, we found that each disease state exhibited a unique expressed genome signature, allowing us to discriminate between the schizophrenia, BPD, and control groups. In addition, we validated changes in several potential biomarker genes for schizophrenia and BPD by RT‐PCR, and some of these were found to code to chromosomal loci previously linked to schizophrenia. Linear and non‐linear combinations of eight putative biomarker genes (APOBEC3B, ADSS, ATM, CLC, CTBP1, DATF1, CXCL1, and S100A9) were able to discriminate between schizophrenia, BPD, and control samples, with an overall accuracy of 95%–97% as indicated by receiver operating characteristic (ROC) curve analysis. We therefore propose that blood cell‐derived RNA may have significant value for performing diagnostic functions and identifying disease biomarkers in schizophrenia and BPD. © 2005 Wiley‐Liss, Inc.
Bibliography:ArticleID:AJMG30161
ark:/67375/WNG-QPG682ZD-Z
istex:0FBCEB1B268981C66D2C6C447745E4029910DEDD
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1552-4841
1552-485X
DOI:10.1002/ajmg.b.30161